{"filings":[{"id":98646,"accession_number":"0001171843-26-003153","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex completes Phase 3 CSU enrollment 6 months early; raises $345M; Q1 net loss $78.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 CSU (EMBARQ-CSU1/2) enrolled 1,939 patients, 6 months ahead of guidance; topline data expected Q4 2026, BLA in 2027.","Raised $345M gross in April 2026 public offering; cash at March 31, 2026 was $451.5M, supplemented by ~$323.9M net proceeds.","Q1 2026 net loss $78.7M ($1.18/share) vs $53.8M ($0.81) in Q1 2025; R&D expenses $73M, up from $52.6M.","Phase 1 CDX-622 proof-of-mechanism study in asthma ongoing; Phase 2 PN data summer 2026, AD data late 2026.","Revenue $0 in Q1 2026 (vs $0.7M); management expects cash to fund operations through 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":15000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98645,"accession_number":"0001104659-26-038882","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celldex prices $300M public offering of 10.3M shares at $29.00 for pipeline and barzolvolimab launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced underwritten public offering of 10,345,000 shares at $29.00/share; gross proceeds ~$300M.","Net proceeds expected ~$282M after underwriting discounts and expenses; closing on or about April 6, 2026.","Underwriters granted 30-day option to purchase up to an additional 1,551,750 shares (15%).","Proceeds to fund commercial readiness and launch of barzolvolimab for CSU (if approved), clinical/preclinical development, and bispecific platform.","Lead managers include Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114246,"accession_number":"0001171843-26-001098","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex completes Phase 3 CSU enrollment six months early; cash $518.6M; net loss $1.22/sh Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 CSU program enrolled 1,939 patients across 43 countries; topline data expected Q4 2026, BLA filing planned 2027.","Phase 2 prurigo nodularis and atopic dermatitis studies fully enrolled; data expected summer and late 2026.","Phase 1 CDX-622 (bispecific SCF & TSLP) proof-of-mechanism study in mild-to-moderate asthma initiated.","Q4 2025 net loss $81.3M ($1.22 per share) vs $47.1M ($0.71) year ago; R&D spend rose to $75.3M.","Cash, cash equivalents and marketable securities $518.6M at Dec 31, 2025; runway through 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":1545000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130616,"accession_number":"0001171843-25-007179","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q3 net loss $67M; barzolvolimab Phase 2 data positive in urticarias","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $67.0M ($1.01/share) vs $42.1M in Q3 2024; cash use $48.6M in operations.","Cash & securities $583.2M as of Sep 30, 2025; runway through 2027.","Phase 2 barzolvolimab met endpoints in CSU, ColdU, and SD; 71% complete response at 52 weeks (CSU).","Phase 1 CDX-622 (bispecific SCF & TSLP) well tolerated; Part 2 enrollment ongoing.","Teri Lawver hired as SVP, Chief Commercial Officer; Phase 3 ColdU/SD study to start Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":1424000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147163,"accession_number":"0001104659-25-080248","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Celldex Phase 2 barzolvolimab in EoE meets primary endpoint but no clinical benefit; advancement stopped","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: peak mast cell count reduced by -36.0 vs placebo -2.7 (p<0.0001) at Week 12.","No improvement in Dysphagia Symptom Questionnaire (DSQ) (p=0.33) or endoscopic EREFS score (p=0.95).","Company will not advance barzolvolimab in EoE; safety profile favorable at 300 mg Q4W.","Pipeline continues in chronic spontaneous urticaria, atopic dermatitis, prurigo nodularis, and inducible urticaria.","Full study (28-week treatment, 44-week total) outcomes consistent with 12-week results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147162,"accession_number":"0001171843-25-005181","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q2 net loss $56.6M ($0.85/share); cash $630.3M; barzolvolimab shows durable complete response at 76 weeks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $56.6M versus $35.8M in Q2 2024; R&D spend rose to $54.2M on barzolvolimab trials.","Cash and securities $630.3M (down $43M QoQ); company expects runway through 2027.","Phase 2 CSU barzolvolimab: up to 41% complete response at 76 weeks (7 months off-treatment); 48% no quality-of-life impact.","Phase 3 CSU program (EMBARQ-CSU1/2) enrolling globally; Phase 2 CIndU and EoE data due in 2H 2025.","Phase 1 CDX-622 (bispecific SCF/TSLP) in healthy volunteers: Part 1 data expected 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":1424000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165745,"accession_number":"0001104659-25-057066","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Celldex shareholders approve equity plan increase, elect directors including Denice Torres","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stockholders approved 2M share increase to 2021 Omnibus Plan (total 9.5M shares) with 53.2M for, 963K against.","All 9 director nominees elected, including new director Denice Torres; Karen Shoos' term ended.","Ratification of PricewaterhouseCoopers as auditor for FY2025: 58M for, 119K against.","Advisory say-on-pay approved: 53.5M for, 627K against.","Harry Penner elected Chair of board post-meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165744,"accession_number":"0001171843-25-002980","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q1 net loss widens to $53.8M; Phase 3 CSU enrollment ongoing, multiple data readouts in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $53.8M ($0.81/share) vs $32.8M ($0.56/share) in Q1 2024; R&D expenses rose to $52.6M.","Cash, equivalents and marketable securities $673.3M at March 31, sufficient to fund operations through 2027.","Phase 3 barzolvolimab CSU studies (EMBARQ-CSU1/2) enrolling; Phase 2 EoE enrollment complete; data expected 2025.","76-week CSU Phase 2 data accepted for late-breaking oral presentation at EAACI June 2025.","Bispecific CDX-622 Phase 1 in healthy volunteers enrolling; Part 1 data expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":695000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183332,"accession_number":"0001171843-25-001126","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex reports Q4 2024 net loss of $47.1M; cash $725.3M; Phase 3 CSU studies enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and securities $725.3M at Dec 31, 2024; company funded through 2027.","Q4 2024 net loss $47.1M ($0.71/sh) vs $43.3M ($0.83/sh) Q4 2023; R&D expenses $46.9M.","Phase 3 CSU studies EMBARQ-CSU1/2 enrolling ~915 patients each across 40 countries.","Phase 3 CIndU program expected to start in 2025; Phase 2 EoE study fully accrued.","Phase 1 CDX-622 (SCF/TSLP bispecific) initiated; multiple data readouts expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":7020000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199920,"accession_number":"0001171843-24-006056","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q3 net loss $42.1M; barzolvolimab meets Phase 2 CIndU endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $42.1M ($0.64 per share) vs $38.3M in Q3 2023; revenue $3.2M vs $1.5M.","Cash $756.0M as of Sep 30, 2024, down from $802.3M; expects to fund operations through 2027.","Barzolvolimab met all primary/secondary endpoints in Phase 2 CIndU; up to 57.6% complete response in SD.","Global Phase 3 CSU trials (EMBARQ-CSU1/2) actively enrolling; CIndU Phase 3 planned for 2025.","First bispecific CDX-622 (SCF/TSLP) entering Phase 1 in Q4 2024; CDX-585 development halted."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":5845000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215931,"accession_number":"0001171843-24-004603","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q2 net loss $0.54 per share; Phase 3 CSU program launched","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $35.8M ($0.54/share) vs $30.5M loss in Q2 2023; revenue $2.5M, up from $0.3M.","Cash $802.3M as of June 30; sufficient to fund operations through 2027.","Initiated global Phase 3 CSU trials (EMBARQ-CSU1/2) in July 2024; actively enrolling.","Phase 2 CIndU study met primary endpoint (negative provocation test) at Week 12; full data 2H 2024.","Barzolvolimab Phase 2 studies ongoing in PN, EoE; AD study to start YE 2024; bispecific CDX-622 enters clinic in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":2654000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235400,"accession_number":"0001104659-24-071512","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Celldex shareholders approve 3.2M share increase to equity plan; director award limits raised","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment increasing share reserve from 4.3M to 7.5M shares under 2021 Omnibus Plan.","Non-employee director annual award limit raised to $750K ($1.2M for new directors) effective after stockholder approval.","All eight director nominees elected, including CEO Anthony Marucci and Chair Karen Shoos, with over 54.6M votes for each.","Advisory say-on-pay vote approved with 54.2M for, 0.9M against; auditor ratification passed with 57.8M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235399,"accession_number":"0001171843-24-002570","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex reports Q1 net loss $32.8M; cash $823.8M; Phase 3 CSU studies planned summer 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $32.8M ($0.56 per share) vs $29.4M ($0.62) in Q1 2023; revenue $0.2M.","Cash, cash equivalents and marketable securities $823.8M, up from $423.6M due to $432.3M net public offering.","Phase 3 CSU studies to initiate summer 2024; 52-week Phase 2 CSU data expected H2 2024.","Phase 2 CIndU enrollment completed (196 patients); 12-week data due H2 2024.","Atopic dermatitis selected as fifth indication; Phase 2 study to start by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":156000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253220,"accession_number":"0001104659-24-029969","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celldex prices upsized $400M common stock offering at $47/share, net proceeds ~$376M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced public offering of 8,520,000 shares at $47.00 per share; upsized from initial $250M to $400M.","Net proceeds expected ~$376.2M after underwriting discounts and expenses.","Underwriters granted 30-day option to purchase up to an additional 1,278,000 shares.","Proceeds to fund clinical/preclinical development of barzolvolimab, bispecific antibody platform, and pipeline.","Offering expected to close on or about March 5, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253219,"accession_number":"0001171843-24-000966","cik":744218,"company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celldex Q4 2023 net loss $43.3M; cash $423.6M; Phase 3 CSU study planned for summer 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net loss $43.3M ($0.83/share) vs $26.5M ($0.56) in Q4 2022; FY net loss $141.4M ($2.92/share).","Revenue $4.1M in Q4 2023 vs $1.6M in Q4 2022, primarily from Rockefeller University manufacturing agreements.","Cash, cash equivalents and marketable securities $423.6M at Dec 31, 2023 vs $235.3M at Sep 30, 2023; $216.2M raised in Nov 2023 offering.","Barzolvolimab: Positive Phase 2 CSU 12-week data; Phase 3 CSU studies expected to start summer 2024; 52-week data in 2H 2024.","Phase 2 CIndU enrollment nearing completion (data 2H 2024); Phase 2 PN study to start early 2024; cash runway into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":6883000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2484274143.228525,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}